Clinical Social Workers in Byram, MS Accepting Medicare
7 Clinical Social Workers found. Showing 1 - 7
 Marie Pickens Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 116 Dakota St, Byram, MS 39272 Phone: 601-278-6739 |
Ms. Sharita Trinette Kincaid, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 321 Martha Dr, Byram, MS 39272 Phone: 601-507-1444 |
Mrs. Tishounna Knox Sulton, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2260 Meagan Dr, Byram, MS 39272 Phone: 769-216-0815 Fax: 601-510-9049 |
Dconstance Woodard, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 117 Ashley Park Dr, Byram, MS 39272 Phone: 601-497-8290 |
Kimberly Mays, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 324 Gator Dr, Byram, MS 39272 Phone: 601-665-5929 |
Lisa Johnson Seaton, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3104 Glennhaven Dr, Byram, MS 39272 Phone: 601-953-0105 |
Pamela Scott, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 812 Bullrun Cir, Byram, MS 39272 Phone: 601-405-4061 |
News Archive
Study shows Alzheimer's disease can lead to diabetes
Drugs used to treat diabetes could also be used to treat Alzheimer's disease, and vice versa, according to new research from the University of Aberdeen.
Ambry Genetics announces launch of Illumina HiSeq 2000 Next Generation Sequencing Services
Ambry Genetics, a global leader in genomic services to the healthcare and life sciences industries, announced today that it has officially launched their Illumina HiSeq 2000 Next Generation Sequencing Services. Ambry Genetics has been an early adapter of Illumina sequencing systems since 2007 and has extensive experience as a Certified Service Provider.
Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
New imaging method that may provide a clearer diagnosis of breast cancer
"This technique involves a new method for interpreting information gathered through MRI," explained Springer. "The technique involves recognizing that certain properties of MRI signals can change during the examination, much like the changing of a camera's shutter speed.
› Verified 7 days ago
Pharmacists
Occupational Therapists
Counselors
Clinical Social Workers
Dentists
Psychologists